However, more basic researches are needed to confirm whether IS has a direct effect on any step of RCT, ApoA-1 mediated cholesterol efflux, HDL biogenesis and maturation, the results of which might bring new target on dyslipidemia therapy in CKD patients. This evidence concerns the gene APOA1 and metabolic syndrome.